Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Infusion of human third-party mesenchymal stromal cells (MSCs) appears to be a promising therapy for acute graft-versus-host disease (aGvHD). To date, little is known about how MSCs interact with the body's innate immune system after clinical infusion. This study shows, that exposure of MSCs to blood type ABO-matched human blood activates the complement system, which triggers complement-mediated lymphoid and myeloid effector cell activation in blood. We found deposition of complement component C3-derived fragments iC3b and C3dg on MSCs and fluid-phase generation of the chemotactic anaphylatoxins C3a and C5a. MSCs bound low amounts of immunoglobulins and lacked expression of complement regulatory proteins MCP (CD46) and DAF (CD55), but were protected from complement lysis via expression of protectin (CD59). Cell-surface-opsonization and anaphylatoxin-formation triggered complement receptor 3 (CD11b/CD18)-mediated effector cell activation in blood. The complement-activating properties of individual MSCs were furthermore correlated with their potency to inhibit PBMC-proliferation in vitro, and both effector cell activation and the immunosuppressive effect could be blocked either by using complement inhibitor Compstatin or by depletion of CD14/CD11b-high myeloid effector cells from mixed lymphocyte reactions. Our study demonstrates for the first time a major role of the complement system in governing the immunomodulatory activity of MSCs and elucidates how complement activation mediates the interaction with other immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 3×
“However, their relationship to the innate immune system has scarcely been addressed so far, focusing primarily on innate effector cells and toll like receptors [9,27].”
BackgroundRen, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Bennet, W., Sundberg, B., Groth, C. G., Brendel, M. D., Brandhorst, D., Brandhorst, H., Bretzel, R. G., Elgue, G., Larsson, R., Nilsson, B., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.10.1907 · Cited by 431 · cited 1×
“This may be due to the instant blood-mediated inflammatory reaction (IBMIR) [17], which is characterized by a rapid destruction of the infused cells due to complement-, coagulationand platelet activation.”
BackgroundSelf-citation
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018
Self-citationConcise Review: Mesenchymal Stem Cells: From Roots to Boost
Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Stem Cells · doi:10.1002/stem.3016 · Cited by 611
Mechanisms of mesenchymal stromal cell immunomodulation
English, K. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2012.56 · Cited by 518
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440
“The complement compatibility of MSCs can be tested [7,40,62,70,86,97 – 99], but MSC testing for example in Chandler blood loops only allows C3a/C5a detection, whereas MSC coculture with lepirudin-anticoagulated blood allows detection of C3a/C5a and CD11b priming on peripheral blood mononuclear…”
InfluentialSelf-citationJungebluth, P., Alici, E., Baiguera, S., Blomberg, P., Bozóky, B., Crowley, C., Einarsson, O., Gudbjartsson, T., Le Guyader, S., Henriksson, G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61715-7 · Cited by 424
Self-citationRetractedBianco, P. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013132 · Cited by 402
Moll, G., Alm, J. J., Davies, L. C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., Hamad, O. A., Hinsch, R., Ignatowicz, L., Locke, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1729 · Cited by 381
Self-citationAre Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
Moll, G., Rasmusson-Duprez, I., von Bahr, L., Connolly-Andersen, A.-M., Elgue, G., Funke, L., Hamad, O. A., Lönnies, H., Magnusson, P. U., Sanchez, J., et al. (2012) · Stem Cells · doi:10.1002/stem.1111 · Cited by 357
Self-citationMesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
“Secondly, the complement cascade capable of initiating innate immune attack and MSC embolization is another major leading cause of IBMIR [43, 153, 154].”
BackgroundInfluentialTherapeutic Applications of Mesenchymal Stromal Cells: Paracrine Effects and Potential Improvements
Doorn, J., Moll, G., Le Blanc, K., van Blitterswijk, C., & de Boer, J. (2012) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2011.0488 · Cited by 307
Self-citationMesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Self-citationDabrowska, S., Andrzejewska, A., Janowski, M., & Lukomska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591065 · Cited by 282
Klos, A., Wende, E., Wareham, K. J., & Monk, P. N. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005223 · Cited by 264
Mesenchymal stromal cells and the innate immune response
Le Blanc, K., & Davies, L. C. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.05.004 · Cited by 262
Self-citationThe multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250
Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment
Nilsson, B., Ekdahl, K. N., & Korsgren, O. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32834c2393 · Cited by 194
Self-citationGarcía-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Kuci, Z., Bonig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., kifi, M., Michel, K., Eising, B., Lucchini, G., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.140368 · Cited by 118
“These results correlated very well with the strikingly high inter-donor differences in the immunosuppressive effects of MSC (range 0-90%).(30) In MLR, the allosuppressive Z.”
ResultMiranda, J. P., Camões, S. P., Gaspar, M. M., Rodrigues, J. S., Carvalheiro, M., Bárcia, R. N., Cruz, P., Cruz, H., Simões, S., & Santos, J. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00018 · Cited by 109
Peripheral nerve repair with cultured schwann cells: getting closer to the clinics
Rodrigues, M. C. O., Rodrigues, A. A., Glover, L. E., Voltarelli, J., & Borlongan, C. V. (2012) · The Scientific World Journal · doi:10.1100/2012/413091 · Cited by 75
NguyenThai, Q., Sharma, N., Luong, D. H., Sodhi, S. S., Kim, J., Kim, N., Oh, S., & Jeong, D. K. (2015) · The Journal of Gene Medicine · doi:10.1002/jgm.2826 · Cited by 28
Metadata
- Authors
- Moll, G., Jitschin, R., von Bahr, L., Rasmusson-Duprez, I., Sundberg, B., Lönnies, L., Elgue, G., Nilsson-Ekdahl, K., Mougiakakos, D., Lambris, J. D., Ringdén, O., Le Blanc, K., & Nilsson, B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-01
- Volume
- 6
- Issue
- 7
- Pages
- e21703
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2045862134
- Cited by
- 155
- References
- 3
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.